SEC Orders Becton Dickinson to Pay $175M Penalty Over Alaris Infusion Pump Misrepresentations
Event summary
- SEC ordered Becton Dickinson to pay a $175M penalty for misrepresenting risks related to its Alaris infusion pump sales from 2016 to early 2020.
- BD's stock fell 12% on February 6, 2020, after the company revised its financial guidance and halted sales of the Alaris pump pending FDA clearance.
- The SEC's Fair Fund, created under the Sarbanes-Oxley Act, will distribute the penalty to harmed investors who purchased BD stock between February 5, 2019, and February 5, 2020.
- Claims for the Fair Fund must be submitted by December 13, 2026.
The big picture
The SEC's action against BD highlights the ongoing scrutiny of medical device companies' disclosures and the risks of regulatory non-compliance. The $175M penalty underscores the financial stakes for companies that misrepresent product risks, particularly in the highly regulated healthcare sector. This case also emphasizes the importance of accurate financial guidance and the potential market impact of regulatory actions on investor confidence.
What we're watching
- Regulatory Compliance
- How BD will address the SEC's findings and prevent future misrepresentations in its disclosures.
- Investor Confidence
- Whether the $175M penalty and distribution to harmed investors will restore confidence in BD's stock.
- Product Approvals
- The pace at which BD can obtain new FDA clearances for its medical devices to avoid similar disruptions.
Related topics